Early-life viral lower respiratory tract infections (LRTIs), particularly those caused by respiratory syncytial virus (RSV) and human rhinovirus (HRV), are major contributors to pediatric morbidity and are strongly linked to asthma. RSV causes about 3.6 million hospitalizations and 100,000 deaths annually in children under 5, mainly in low- and middle-income countries. RSV peaks in infancy, while HRV has more impact later in childhood. Mechanisms include viral epithelial injury, genetic susceptibility (e.g., 17q21 variants), and environmental factors (e.g., allergic sensitization). Together, these raise asthma risk. Diagnosis is difficult due to overlapping presentations and reliance on molecular tests. Preventive strategies include maternal RSV vaccination, long-acting monoclonal antibodies such as nirsevimab and palivizumab, and pediatric vaccine candidates. Strategies to limit allergic sensitization may lower HRV-related asthma risk. Long-term effects include persistent wheeze and asthma, making early life a crucial window for prevention.
Methods:
This review summarizes current evidence on the epidemiology, mechanisms, and long-term impact of early viral LRTIs.
Results:
It highlights molecular and immunological endotypes of virus-induced asthma and explores the influence of genetic, epigenetic, and microbial factors. Emerging diagnostic tools and preventive strategies—including vaccines, monoclonal antibodies, environmental interventions, and microbiome-targeted therapies—are also discussed as means to reduce the global pediatric asthma burden and improve respiratory health.
ShiT, McAllisterDA, O’BrienKL, et al.Global burden of respiratory syncytial virus-associated acute lower respiratory tract infections in young children: A systematic review and meta-analysis. Lancet2017;390:946–958.
2.
LiX, WangH, ChenH, et al.Global disease burden of pediatric respiratory syncytial virus in 2019: A systematic analysis. Lancet2022;399:2047–2064.
3.
KhetsurianiN, KazerouniNN, ErdmanDD, et al.Respiratory syncytial virus and human rhinoviruses as major pathogens in pediatric respiratory infections. Curr Opin Allergy Clin Immunol2006;6:223–229.
4.
BerdnikovsS, NewcombDC, HartertTV. How early-life respiratory viral infections impact airway epithelial development and may lead to asthma. Front Pediatr2024;12:1441293.
5.
MartinezFD. The origins of asthma and chronic obstructive pulmonary disease in early life. Proc Am Thorac Soc2009;6(3):272–277.
6.
BacharierLB, CohenR, SchweigerT, et al.Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol2012;130(1):91–100.e3.
7.
BinnsE, TuckermanJ, LicciardiPV, et al.Respiratory syncytial virus, recurrent wheeze and asthma: Pathophysiology, prevention and future directions. J Paediatr Child Health2022;58(10):1741–1746.
8.
BeigelmanA, BacharierLB. Early-life respiratory infections and asthma development: Role in disease pathogenesis and potential targets for disease prevention. Curr Opin Allergy Clin Immunol2016;16(2):172–178.
9.
JacksonDJ. Early-life viral infections and the development of asthma: A target for asthma prevention? Curr Opin Allergy Clin Immunol2014;14(2):131–136.
10.
JacksonDJ, SykesA, MalliaP, et al.Gene-environment interactions in asthma pathogenesis. J Allergy Clin Immunol2018;141:1119–1130.
11.
MillerMD, SaloPM, HamiltonRG, et al.Environmental risk factors for asthma. Pediatrics2021;148:e2021051488.
12.
GarcíaE, BerhaneK, NetheryRC, et al.Indoor air pollution and child respiratory health. Lancet Glob Health2022;10:e682–e692.
13.
SahaS, AluisioAR, ChavesSS, et al.Epidemiology, diagnostics, and management of childhood pneumonia in low- and middle-income countries. Clin Infect Dis2024;78:1234–1245.
14.
WeinbergGA, WalkerCLF, VictorJC, et al.Respiratory tract infections and laboratory diagnostic methods in low-resource settings. Front Microbiol2018;9:2478.
15.
HartertTV, OrtizJR. Need for improved global measurement of early childhood respiratory syncytial virus disease. Lancet2022;399(10340):1993–1995.
16.
WangY, XiangY, JinR, et al.Risk factors for severe lower respiratory tract infection among children under 5 years of age hospitalized with respiratory syncytial virus. Eur J Clin Microbiol Infect Dis2025;44(9):2239–2251.
17.
WangY, LiJ, ChenZ, et al.Molecular diagnostics and microbiome-based personalized medicine in respiratory infections. Front Microbiol2020;11:596166.
18.
LiY, ShiT, KnibbsLD, et al.Early-life respiratory syncytial virus disease and long-term respiratory health. Lancet Respir Med2024;12:789–799.
19.
OddyWH. Breastfeeding, childhood asthma, and allergic disease. Ann Nutr Metab2017;70 (Suppl 2)(Suppl 2):26–36.
20.
VictoraCG, BahlR, BarrosAJD, Lancet Breastfeeding Series Group. et al.; Breastfeeding in the 21st century: Epidemiology, mechanisms, and lifelong effect. Lancet2016;387(10017):475–490.
DuanQ, PanJ, ZhengL, et al.Global outbreaks of respiratory syncytial virus infections from 1960 to 2025: A systematic review and meta-analysis. EClinicalMedicine2025;86:103352.
23.
HamidS, WinnA, ParikhR, et al.Seasonality of respiratory syncytial virus-United States, 2017-2023. MMWR Morb Mortal Wkly Rep2023;72(14):355–361.
24.
DeshmukhH, BushA, ErzurumS, et al.Impact of early-childhood lower respiratory tract infection on lung growth: NIH workshop summary. Pediatr Pulmonol2024;59:e164–e176.
25.
ThindwaD, LiK, Cooper-WoottonD, et al.Global patterns of rebound to normal respiratory syncytial virus dynamics following COVID-19 suppression. BMC Infect Dis2024;24:635.
26.
PapadopoulosNG, BacharierLB, JacksonDJ, et al.Type 2 inflammation and asthma in children: A narrative review. J Allergy Clin Immunol Pract2024;12(9):2310–2324.
27.
McNamaraPS, FlanaganBF, BaldwinLM, et al.Cytokine biomarkers in infants with respiratory syncytial virus infection. J Infect Dis2014;210:1365–1374.
28.
PiedimonteG, PerezM. Early-life viral infection and asthma development: Mechanistic insights and therapeutic opportunities. Am J Physiol Lung Cell Mol Physiol2024;326:L1–L15.
29.
McDonaldVM, ClarkVL, GibsonPG. Integrated care for chronic respiratory diseases: A narrative review. Respir Med2021;190:106678.
30.
OlsthoornSEM, Van KrimpenA, HendriksRW, et al.Chronic inflammation in asthma: Looking beyond the Th2 cell. Immunol Rev2025;330(1):e70010.
31.
AsseriA. Characteristics of allergic, eosinophilic, and overlapping asthma phenotypes among pediatric patients. J Asthma Allergy2023;16:1297–1308.
32.
YangIV, SchwartzDA. Epigenetic mechanisms and the development of asthma. J Allergy Clin Immunol2012;130(6):1243–1255.
33.
Rosas-SalazarC, ChirkovaT, GebretsadikT, et al.Respiratory syncytial virus infection during infancy and asthma during childhood in the USA (INSPIRE): A population-based prospective birth cohort study. Lancet2023;401(10389):1669–1680.
34.
KuruvillaME, LeeFEH, LeeGB. Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol2019;56(2):219–233.
35.
FoppianoF, SchaubB. Childhood asthma phenotypes and endotypes: A glance into the mosaic. Mol Cell Pediatr2023;10(1):9.
36.
StokholmJ, BlaserMJ, ThorsenJ, et al.The airway microbiome and asthma development. Allergy2018;73:629–637.
37.
TeoSM, MokD, PhamK, et al.The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. Cell Host Microbe2015;17(5):704–715.
38.
HasegawaK, MansbachJM, AjamiNJ, et al.Nasopharyngeal microbiota profiles and bronchiolitis severity. Eur Respir J2016;48:1329–1339.
39.
DurackJ, LynchSV. The respiratory microbiome and asthma. Nat Rev Immunol2020;20:74–88.
40.
BoschAATM, BiesbroekG, TrzcinskiK, et al.Viral-bacterial interactions in the upper respiratory tract. PLoS Pathog2018;14:e1007302.
41.
XuCJ, ScheltemaNM, QiC, et al.Infant respiratory syncytial virus immunoprophylaxis changes nasal epithelial DNA methylation at 6 years of age. Eur Respir J2021;56:2003182.
42.
MadhiSA, PolackFP, KarronRA, et al.Immunogenicity of pediatric respiratory syncytial virus vaccine candidates. Lancet2023;403:123–134.
43.
HigginsD, TrujilloC, KeechC, et al.Advances in pediatric respiratory syncytial virus vaccine development. Nat Rev Drug Discov2024;23:45–57.
44.
JolliffeDA, CamargoCAJr, SluyterJD, et al.Vitamin D supplementation and respiratory infection risk. Lancet Diabetes Endocrinol2021;9:276–292.
45.
FujimuraKE, LynchSV. Gut microbiota and allergic disease. Nat Rev Gastroenterol Hepatol2022;19:77–92.
46.
MuñozFM, SwamyGK, ThompsonMG, et al.Safety and immunogenicity of respiratory syncytial virus vaccines. Lancet Infect Dis2023;23:305–316.
47.
KampmannB, RadleyD, MunjalI, et al.Bivalent prefusion F respiratory syncytial virus vaccine in pregnancy. N Engl J Med2023;388:1451–1464.
48.
HammittLL, DaganR, YuanY, et al.Nirsevimab for prevention of respiratory syncytial virus in infants. N Engl J Med2022;386:837–846.
49.
GriffinMP, YuanY, TakasT, et al.Single-dose nirsevimab efficacy and safety in healthy infants. Lancet2023;401:1229–1237.
50.
ZeevatF, Van Der PolS, KiefferA, et al.Cost-effectiveness analysis of nirsevimab for preventing respiratory syncytial virus-related lower respiratory tract disease in Dutch infants. Pharmacoeconomics2025;43(5):569–582.
51.
YunKW, KangD. Direct out-of-pocket costs of nirsevimab versus palivizumab during the first respiratory syncytial virus season: A comparative analysis. Infect Chemother2025;57(2):305–309.
52.
SauréD, O’RyanM, TorresJP, et al.Cost-savings and health impact of strategies for prevention of respiratory syncytial virus with nirsevimab in Chile. J Infect Public Health2025;18:102680.
53.
LeeWM, LemanskeRFJr, EvansMD, et al.Advances in human rhinovirus therapeutics. J Infect Dis2023;227:543–551.
54.
LeeE, GernJE. Clinical significance of rhinoviruses and progress toward vaccination. Allergy Asthma Immunol Res2025;17(4):414–432.
55.
MamunTI, AliMA, HosenMN, et al.Designing a multi-epitope vaccine candidate against human rhinovirus C utilizing an immunoinformatics approach. Front Immunol2024;15:1364129.
56.
LiuY, ChenX, WangJ, et al.Bacterial-viral interactions in respiratory infections. Front Cell Infect Microbiol2024;14:1435294.
57.
EsneauC, BryantNE, JohnstonSL, et al.Opportunities for rhinovirus-targeted RNA therapeutics: A narrative review. CMI Commun2025;2(3):105081.
58.
BisgaardH, StokholmJ, ChawesBL, et al.Fish oil-derived fatty acids in pregnancy and wheeze and asthma in offspring. N Engl J Med2016;375(26):2530–2539.
59.
WestCE, JenmalmMC, KozyrskyjAL, et al.Probiotics for prevention of respiratory tract infections. Curr Opin Allergy Clin Immunol2016;16:232–238.
60.
LassiZS, MoinA, BhuttaZA. Community interventions for child health. BMJ Glob Health2020;5:e003621.
61.
ManWH, de Steenhuijsen PiersWAA, BogaertD. Respiratory-tract microbiota: Gatekeeper to respiratory health. Nat Rev Microbiol2017;15:259–270.
62.
CampbellCD, GleesonM, SulaimanI. The respiratory microbiome in asthma. Front Allergy2023;4:1120999.
63.
Gil-PrietoR, Pérez-MartínJ, Díaz AguilóA, et al.Estimating the economically justifiable price of nirsevimab versus standard of practice in Spain. BMJ Public Health2025;3:e002441.
64.
ChartrandC, LeeflangMM, MinionJ, et al.Accuracy of rapid influenza diagnostic tests: Meta-analysis. Ann Intern Med2012;156(7):500–511.
65.
TuriKN, ShankarJ, AndersonLJ, et al.Infant nasal immune patterns and recurrent wheeze risk. Am J Respir Crit Care Med2018;198:1064–1073.
66.
The Medical Letter. Treatment of common respiratory tract infections. Med Lett Drugs Ther2023;65(1674a):1–6.
67.
McCallumGB, MorrisPS, VersteeghLA, et al.Management of acute pediatric lower respiratory tract infections: A review of guidelines. Pneumon2020;33:163–184.
68.
The Lancet. Antibiotics for lower respiratory tract infections in children in primary care. Lancet2021;398:1234–1245.
69.
WilkinsonTMA, BloomCI, BaldwinM, et al.Integrated care models for chronic respiratory diseases: Lessons from chronic obstructive pulmonary disease. Lancet Respir Med2019;7:1003–1012.
70.
DonathH, KlugeS, SideriG, et al.Hospitalization, asthma phenotypes, and readmission rates in preschool asthma. Front Pediatr2020;8:562843.
71.
McLeanGR. Vaccine strategies to induce broadly protective immunity to rhinoviruses. Hum Vaccin Immunother2020;16(3):684–686.
72.
HanHJ, JangS, DahyeR, et al.Cost-effectiveness of nirsevimab for preventing respiratory syncytial virus-associated lower respiratory tract infections in infants and palivizumab-eligible children in South Korea. Hum Vaccin Immunother2024;21:2545637.
